Maia Fertility
Enzyme Therapy Designed to Improve Embryo Implantation in Human and Animal Fertility Care
Company Overview
Snapshot
Founded in September 2025, Maia Fertility operates with 1–10 employees. In August 2026, the company secured seed funding from Mercantile Life Science Ventures IV (MLSV) and Big Idea Ventures, marking a significant early-stage validation for its biotechnology platform.
Business overview
Maia Fertility is a biotechnology company focused on developing enzyme-based treatments to enhance embryo implantation, addressing a key challenge in assisted reproduction. Its core product, Fertizyme, is a recombinant protein engineered to mimic uterine enzymes, thereby improving uterine receptivity by remodeling the endometrial extracellular matrix before implantation. The company initially targets the livestock reproduction market, including dairy cattle and high-value horse and camel breeding in North America and Europe, with plans to extend its applications to human IVF. Maia Fertility serves fertility clinics, veterinary reproductive specialists, breeders, and livestock operators seeking to improve conception rates and reproductive efficiency.
Strategic signal
Maia Fertility's seed funding in August 2026 from Mercantile Life Science Ventures IV (MLSV). This investment validates the potential of Fertizyme to address critical reproductive challenges in both animal and future human applications, positioning the company for accelerated development and market expansion, particularly within the high-value livestock sector.
Company Intelligence Q&A
- What is Maia Fertility's primary focus?
- Maia Fertility is a biotechnology company developing enzyme-based treatments to improve embryo implantation in both human and animal fertility care.
- When did Maia Fertility receive its most recent funding?
- Maia Fertility received seed funding in August 2026 from Mercantile Life Science Ventures IV (MLSV) and Big Idea Ventures.
- What is Fertizyme?
- Fertizyme is Maia Fertility's recombinant protein designed to emulate uterine enzymes and remodel the endometrial extracellular matrix, aiming to improve uterine receptivity before embryo implantation.
- Which markets does Maia Fertility currently target?
- Maia Fertility's near-term market is livestock reproduction, including dairy cattle and high-value horse and camel breeding in North America and Europe, with future applications planned for human IVF.
- What is the current development stage of Maia Fertility's product?
- Maia Fertility reports completed preclinical studies in animal models and is expanding efficacy studies across commercial cattle operations, indicating its product is in the clinical trial stage.